Everolimus for renal angiomyolipoma in tuberous sclerosis
Mené sur 118 patients atteints d'un angiomyolipome rénal, cet essai de phase III évalue l'évérolimus du point de vue du taux de réduction du volume tumoral
In The Lancet , John Bissler and colleagues 1 report the first randomised, double-blind, placebo-controlled, phase 3 trial of everolimus, an inhibitor of mammalian target of rapamycin (mTOR), in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis, and angiomyolipoma. Their findings suggest a clear advantage for everolimus over placebo in reducing angiomyolipoma volume with an acceptable safety profile in patients with tuberous sclerosis...
The Lancet , commentaire, 2012